UCB S.A. is a global biopharmaceutical company headquartered in Brussels, Belgium, specializing in the research, development and commercialization of treatments for severe diseases in immunology and neurology. The company’s portfolio includes therapies for conditions such as rheumatoid arthritis, Crohn’s disease and various forms of epilepsy. UCB’s flagship products include CIMZIA® (certolizumab pegol) for autoimmune disorders, KEPPRA® (levetiracetam) and VIMPAT® (lacosamide) for seizure management, among others under development targeting central and peripheral nervous system disorders.
Founded in 1928 as Union Chimique Belge, UCB initially focused on chemicals and pharmaceuticals before evolving into a dedicated biopharma enterprise. Over the decades, the company has expanded through research partnerships, strategic acquisitions and in-house innovation, building a pipeline of investigational drugs aimed at unmet medical needs. Its R&D operations span Belgium, the United States and Asia, with key research facilities located in Braine-l’Alleud (Belgium) and Raleigh (North Carolina, U.S.).
UCB markets its products across more than 40 countries, with commercial and manufacturing facilities in Europe, North America and Asia-Pacific. The company employs a multi-regional approach to supply chain management and patient support programs, working closely with health authorities, physicians and patient organizations to facilitate access to its therapies. UCB also invests in digital health initiatives and biomarker research to enhance personalized treatment and patient outcomes.
As of the latest available information, UCB is led by President and Chief Executive Officer Jean-Christophe Tellier, under whose guidance the company continues to pursue sustainable growth and scientific innovation. Governance is overseen by a Board of Directors representing diverse expertise in biopharma, finance and global healthcare. UCB remains committed to advancing its pipeline and strengthening its global footprint in pursuit of improving the lives of patients with chronic and severe diseases.
AI Generated. May Contain Errors.
